|
|
 |
|
Viewing report
|
|
|
|
Global Ovarian Cancer Drug Pipeline Capsule - 2011
Fore Pharma, Aug 2011, Pages: 13
Fore Pharma’s latest report ‘Global Ovarian Cancer Drug Pipeline Capsule – 2011’ is an outline of all the key research and development (R&D) activities of the global ovarian cancer drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.
This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.
The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the ovarian cancer drug market is thoroughly covered by company and licensee with the deal summary.
Key Features of the Report:
- Ovarian Cancer: Overview
- Ovarian Cancer Drug Pipeline Overview
- Ovarian Cancer Phase 3 Clinical Trial Drug Pipeline Insights
- Ovarian Cancer Phase 2 Clinical Trial Drug Pipeline Insights
- Ovarian Cancer Phase 1 Clinical Trial Drug Pipeline Insights
- Ovarian Cancer Preclinical Research Drug Pipeline Insights
- Ovarian Cancer Drug Discovery Pipeline Insights
- Geographic Landscape of Ovarian Cancer R&D Activities
- Ovarian Cancer R&D Activities in North America
- Ovarian Cancer R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Ovarian Cancer Drug Market
|
|
|
|
